GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Freeline Therapeutics Holdings PLC (NAS:FRLN) » Definitions » Accumulated other comprehensive income (loss)

Freeline Therapeutics Holdings (Freeline Therapeutics Holdings) Accumulated other comprehensive income (loss) : $-1.57 Mil (As of Sep. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Freeline Therapeutics Holdings Accumulated other comprehensive income (loss)?

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings. Freeline Therapeutics Holdings's Accumulated other comprehensive income (loss) for the quarter that ended in Sep. 2023 was $-1.57 Mil.

Freeline Therapeutics Holdings's quarterly Accumulated other comprehensive income (loss) increased from Mar. 2023 ($-1.72 Mil) to Jun. 2023 ($-0.78 Mil) but then declined from Jun. 2023 ($-0.78 Mil) to Sep. 2023 ($-1.57 Mil).

Freeline Therapeutics Holdings's annual Accumulated other comprehensive income (loss) increased from Dec. 2020 ($9.34 Mil) to Dec. 2021 ($9.47 Mil) but then declined from Dec. 2021 ($9.47 Mil) to Dec. 2022 ($-3.15 Mil).

Freeline Therapeutics Holdings Accumulated other comprehensive income (loss) Historical Data

The historical data trend for Freeline Therapeutics Holdings's Accumulated other comprehensive income (loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Freeline Therapeutics Holdings Accumulated other comprehensive income (loss) Chart

Freeline Therapeutics Holdings Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22
Accumulated other comprehensive income (loss)
-2.85 -3.00 9.34 9.47 -3.15

Freeline Therapeutics Holdings Quarterly Data
Dec18 Jun19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Accumulated other comprehensive income (loss) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.85 -3.15 -1.72 -0.78 -1.57

Freeline Therapeutics Holdings Accumulated other comprehensive income (loss) Calculation

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings.

Freeline Therapeutics Holdings Accumulated other comprehensive income (loss) Related Terms

Thank you for viewing the detailed overview of Freeline Therapeutics Holdings's Accumulated other comprehensive income (loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Freeline Therapeutics Holdings (Freeline Therapeutics Holdings) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Freeline Therapeutics Holdings PLC (NAS:FRLN) » Definitions » Accumulated other comprehensive income (loss)
Comparable Companies
NBIO AIM NLSP ACST NTBL UNCY BIXT PIRS SKYE ELEV OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
Gunnels Wood Road, Sycamore House, Stevenage, Hertfordshire, GBR, SG1 2BP
Website
https://www.freeline.life
Freeline Therapeutics Holdings PLC is a clinical-stage biotechnology company developing transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its lead product candidates are FLT180a for the treatment of hemophilia B, FLT190 for the treatment of Fabry disease and FLT201 for the treatment of Gaucher disease Type 1.